tiprankstipranks
Trending News
More News >

Edgewise Therapeutics Announces Positive Phase 2 Trial Results

Story Highlights
  • Edgewise Therapeutics announced positive results from a Phase 2 trial of EDG-7500 for hypertrophic cardiomyopathy.
  • EDG-7500 showed significant improvements in cardiac function without affecting systolic function, indicating potential for HCM treatment.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Edgewise Therapeutics Announces Positive Phase 2 Trial Results

Confident Investing Starts Here:

Edgewise Therapeutics ( (EWTX) ) has provided an announcement.

On April 2, 2025, Edgewise Therapeutics announced positive top-line results from its Phase 2 CIRRUS-HCM trial of EDG-7500 in patients with both obstructive and nonobstructive hypertrophic cardiomyopathy. The trial demonstrated that EDG-7500 significantly reduced left ventricular outflow tract gradients and improved cardiac biomarkers without affecting systolic function, indicating its potential as a significant advancement for HCM treatment. The findings suggest a promising future for EDG-7500, with plans for further optimization and a Phase 3 trial in 2026, potentially impacting patients and clinicians by providing a new therapeutic option.

More about Edgewise Therapeutics

Edgewise Therapeutics is a leading biopharmaceutical company specializing in muscle disease treatments. The company focuses on developing novel therapies, such as EDG-7500, a cardiac sarcomere modulator designed to address hypertrophic cardiomyopathy (HCM) and other diastolic dysfunction diseases.

YTD Price Performance: -25.53%

Average Trading Volume: 1,186,032

Technical Sentiment Signal: Hold

Current Market Cap: $2.09B

See more insights into EWTX stock on TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App